Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma. This is according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Before the results of this study, we knew that cobimetinib plus vemurafenib could be safely delivered together with highly promising rates of tumour shrinkage; ...
Read MoreYou have just read an article categorized health
titled New Data on Combination Therapies for Melanoma.
Written by:
editor - Tuesday, September 30, 2014
There are currently no comments for "New Data on Combination Therapies for Melanoma"
Post a Comment